Liraglutide,GLP-1受体激动剂

Liraglutide(204656-20-2)是人胰高血糖素样肽 (GLP-1) 的长效类似物。它作为GLP-1受体激动剂。利拉鲁肽在体外减弱人血管内皮细胞中纤溶酶原激活物抑制剂1型和血管粘附分子表达的诱导，并可能防止内皮细胞功能障碍。Liraglutide通过血管内皮细胞系抑制 TNFα 诱导的 ICAM-1 和 VCAM-1 mRNA 和蛋白质表达。

溶解度:生物体外In Vitro:H2O5 mg/mL(1.33 mM;ultrasonic and adjust pH to 8 with NaOH)

性状:Solid power

储藏条件:Storage conditionsprotect from light避光 粉末Powder: -80°C 2years年 -20°C 1 year / In solvent溶液中: -80°C 6 months月 -20°C 1 month月

案例：

Figure 1 Effects of liraglutide and telmisartan on body weight, blood sugar, MDA, SOD, NT-pro-BNP, and cardiac hypertrophy after abdominal aortic constriction (AAC). (A) body weight and blood glucose were measured among different groups. (B and C) Levels of MDA, SOD, and NT-pro-BNP activity in myocardial tissue were determined using Elisa kits. (D) MSA in series was measured morphometrically at a HPF (original magnification: 200; scale bars: 100 μm). (E) Heart/body weight ratio (HW/BW, mg/g) was calculated by weight. Values are mean±SEM (n=6/group). *p<0.05 AAC vs Sham; #p<0.05 liraglutide (Lira) or telmisartan (Telmi) vs AAC. Abbreviations: MDA, malonaldehyde; SOD, superoxide dismutase; NT-pro-BNP, N-terminal pro-B-type natriuretic peptide; MSA, myocyte sectional area.